A federal judge in the USA has set aside a jury verdict that awarded $340,000 to a scientist fired by Johnson & Johnson subsidiary Therakos. The researcher had claimed he was dismissed because he opposed sending government regulators inadequate test results to get a fast approval of a medical device, and that the termination violated J&J's corporate beliefs and credo. He plans to appeal.
Meantime, Eli Lilly has disciplined two of its salesman for improperly promoting the antidepressant Prozac (fluoxetine) to high school students during a school seminar on depression. The salesmen, filling in for a doctor who had been scheduled to speak, lectured the students and handed out note-pads and pens with Prozac's name on them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze